• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.


    June 17, 2019

     

    Media Contact: 

    Deidre McCabe, Director, Office of Communications,410-767-3536

     

    Maryland newborns to be screened for four additional conditions 

    MDH increases identifiable conditions in panel to 61

     

    Baltimore, MD– The Maryland Department of Health (MDH) announced today that newborns will be screened for four additional conditions under Maryland’s newborn screening program. Newborn screening helps identify certain rare conditions so treatment can start immediately.

     

    Mucopolysaccharidosis type I (MPS I) and Spinal Muscular Atrophy(SMA), bringing the total number of conditions in the panel to 61. The addition of these tests puts Maryland in the top five states in the nation for the number of screening tests available to newborns.

     

    “We’re thrilled to add these four conditions to the screening panel, further ensuring babies born in Maryland are as healthy as possible,” said MDH Secretary Robert R. Neall. “This screening is the fastest way to alert parents and providers to the presence of any of these conditions. I encourage all new parents to learn about and take advantage of newborn screening.” 

     

    Newborn screening is performed by obtaining a few drops of blood from the baby’s heel. The blood sample is placed on special paper, dried and mailed to the Maryland State Laboratory, where the testing is performed. The newborn screen looks for conditions that can occur because of problems with the body’s hormones, inability to break down food correctly, certain kinds of blood disorders, and other types of inherited conditions.

     

    “Disorders on the newborn screening panel are selected because there is treatment available to prevent symptoms of the medical condition or to help make the symptoms less severe,” said Fran Phillips, MDH Deputy Secretary for Public Health. “The goal is to identify babies while they are still healthy and make sure they receive specialized care as quickly as possible, if one of these disorders is detected or further testing is needed.”

     

    While newborn screening does not diagnose conditions, it plays a crucial role in identifying babies who need further testing. Between June 2018 and May 2019, approximately 78,000 babies were screened in Maryland labs. Of those screened, 240 newborns were found to have one of the conditions included in the screening panel.

     

    Each baby born in Maryland should get two newborn screens. The first screen is collected when the baby is just over 24 hours old. The second should be collected at the doctor’s office when the baby is around two weeks old. If the newborn screen results show anything out of the normal range, the MDH Newborn Screening Follow-Up Program will contact the baby’s doctor to provide follow up and specialized consultation to ensure each baby receives the best care.

     

    The four disorders added to the panel (bringing the total to 61) include:

     

    ·     Pompe disease – The body is not able to break down a certain complex sugar. This sugar builds up in cells and causes damage when it accumulates in certain parts of the body, including muscles. 

    ·     Fabry disease – The body is not able to break down a certain fatty substance. This substance accumulates in cells and can cause damage throughout the body, including to the heart, kidneys, nervous system, and skin. 

    ·     Mucopolysaccharidosis type I(MPS 1) – The body is not able to break down certain large sugar molecules. These sugar molecules build up in cells and cause different organs and tissues to become enlarged. Many parts of the body can be impacted.

    ·     Spinal Muscular Atrophy (SMA) – There is a loss of specialized nerve cells called motor neurons in the spinal cord. These motor neurons control muscle movement. Their loss results in weakness and wasting of muscles, and can impact muscles used for breathing. 

     

    Additional information about Maryland’s newborn screening program can be found on the Department’s website at https://health.maryland.gov/laboratories/Pages/Parents.aspx

     

    ###


    The Maryland Department of Health is the state agency that protects Maryland’s public health. We work together to promote and improve the health and safety of all Marylanders through disease prevention, access to care, quality management, and community engagement. Stay connected: http://www.twitter.com/MDHealthDept and http://www.facebook.com/MarylandDHMH. 

    Marylanders in need of treatment for a substance use disorder can locate treatment facilities on our page a visit http://goo.gl/nIfGm0. Individuals can also call 211 and press 1 or text their zip code to 898-211 to speak with knowledgeable crisis call specialists. For information on many of the policies currently implemented to fight addiction and overdose in Maryland, see http://goo.gl/KvEzQw. ​